Nurix Therapeutics (NRIX) Research & Development (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Research & Development data on file, last reported at $84.1 million in Q1 2026.

• Research & Development for Q1 2026 came in at $84.1 million, up 20.78% year-over-year; the trailing twelve-month figure through Feb 2026 was $331.4 million (up 37.34% YoY), and the FY2025 annual result was $316.9 million, up 42.99% from the prior year.
• Research & Development improved to $84.1 million in Q1 2026 per NRIX's latest filing, from $83.0 million in the prior quarter.
• Over five years, Research & Development peaked at $86.1 million in Q3 2025 and troughed at $43.1 million in Q1 2022.
• A 5-year average of $58.6 million and a median of $49.7 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2023: Research & Development soared 87.53% in 2022, then dropped 3.64% in 2023.
• A 5-year view of Research & Development shows it stood at $46.1 million in 2022, then grew by 7.82% to $49.7 million in 2023, then soared by 35.22% to $67.2 million in 2024, then advanced by 23.5% to $83.0 million in 2025, then advanced by 1.34% to $84.1 million in 2026.
• Business Quant data shows NRIX's Research & Development at $84.1 million in Q1 2026, $83.0 million in Q4 2025, and $86.1 million in Q3 2025.